Article info
PDFBenefits to participants
Paper
For love and money: the need to rethink benefits in HIV cure studies
- Correspondence to Emily Largent, Program in Health Policy, Harvard University, Cambridge MA 02138, USA; elargent{at}fas.harvard.edu
Citation
For love and money: the need to rethink benefits in HIV cure studies
Publication history
- Received October 2, 2015
- Revised January 28, 2016
- Accepted February 18, 2016
- First published May 18, 2016.
Online issue publication
January 25, 2017
Article Versions
- Previous version (25 January 2017).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Other content recommended for you
- Are therapeutic motivation and having one's own doctor as researcher sources of therapeutic misconception?
- An investigation of patients’ motivations for their participation in genetics-related research
- Phase I oncology trials: why the therapeutic misconception will not go away
- Are positive experiences of children in non-therapeutic research justifiable research benefits?
- What constitutes a reasonable compensation for non-commercial oocyte donors: an analogy with living organ donation and medical research participation
- Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment
- What makes clinical labour different? The case of human guinea pigging
- An activist's argument that participant values should guide risk–benefit ratio calculations in HIV cure research
- Scientific research is a moral duty
- Undue inducement: a case study in CAPRISA 008